Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer

@inproceedings{Mayer2012AbstractOT,
  title={Abstract OT2-3-11: Tivozanib in combination with paclitaxel vs placebo with paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer},
  author={El Mayer and Kathy D. Miller and Joyce O'Shaughnessy and Maura N. Dickler and Charles L. Vogel and Brian Leyland-Jones and Lala Carr Steelman and Max Robinson and Nagato Kuriyama and Sushil Kumar Agarwal},
  year={2012}
}
Background: Triple-negative breast cancer (TNBC) is an aggressive cancer with inferior survival outcomes. Although weekly paclitaxel (WP) is effective in the treatment (tx) of metastatic breast cancer (MBC), optimization of therapies for patients (pts) with TNBC is essential. Angiogenesis is a hallmark of advanced cancer, with subset analyses suggesting activity of angiogenesis inhibitors in TNBC. Tivozanib (TIVO) is a potent and selective inhibitor of vascular endothelial growth factor… CONTINUE READING

Similar Papers

Topics from this paper.